Kliniken der Stadt Koeln gGmbH — Clinical Trial Site

80 Registered trials

30 Currently recruiting

Organisation

Kliniken der Stadt Koeln gGmbH

Location

Cologne, Germany

Identifier

ORG-100025922

Address

Ostmerheimer Strasse 200, Merheim, 51109, Germany

Departments

#4502: Lungenklinik Koln-Merheim
2048"Medizinische Klinik I, Transplantationszentrum
2601:Lungenklinik Köln-Merheim, Studienzentrum
2606: Lungenklinik Köln-Merheim
407: Augenklinik
Ambulanz für Hämatologie und Onkologie
Apotheke
Breast Center Holweide
Brustzentrum Holweide
Brustzentrum Köln-Holweide
Department of Anesthesiology and Critical Care Medicine, Merheim Medical Center
Department of Ophtalmology
Department of Traumatology and Orthopedic Surgery Cologne-Merheim Medical Center (CMMC)
Gastroenterologie
Internal MedicineSection of Hematology and Oncology, Holweide
Kinder-Hämatologie und Onkologie, Kinderkrankenhaus Amsterdamer Straße
Kinderkrankenhaus
Kinderonkologie Station A5
Klinik für Kinder- und Jugendmedizin I - Onkologie- Hämatologie
Klinik für Viszeral-, Tumor-, Transplantations- und Gefäßchirurgie
Kliniken der Stadt Koeln gGmbH
Kliniken der Stadt Köln - Krankenhaus Köln-Holweide, Medizinische Klinik Brustzentrum
Krankenhaus Koeln-Merheim
Krankenhaus Köln-Holweide,Medizinische Klinik Brustzentrum
Krankenhaus Köln-Merheim / Lungenklinik
Krankenhaus Köln-Merheim Lungenklinik - Lungenkrebszentrum
Krankenhaus Köln-Merheim Lungenklinik Lungenkrebszentrum
Krankenhaus Merheim Lungenklinik
Lungenklinik
Lungenklinik - Abt. Pneumologie
Lungenklinik / Lungenkrebszentrum Köln- Merheim
Lungenklinik Köln Merheim
Lungenklinik Köln-Merheim
Lungenklinik Merheim / Haus 29B
Lungenklinik Merheim Studienzentrum der Thoraxchirugischen Klinik
Lungenklinik/ Lungenkrebszentrum Koeln- Merheim
Lungenklinik/ Lungenkrebszentrum Köln- Merheim
Lungenkrebszentrum
Lungenkrebszentrum Köln Merheim
Lungenkrebszentrum Krankenhaus Köln Merheim
Lungenzentrum Merheim
Medizinische Klinik I
Medizinische Klinik/Studienzentrum
Mesotheliomeinheit Koeln – Merheim
Mesotheliomeinheit Köln – Merheim
N/A
Oncology
Oncology Outpatient Clinic
Onkologische Ambulanz
Paedriatrics, Department of Oncology and Hematology
pediatric hematologie/Oncology
Studienzentrum der Lungenklinik
Studienzentrum der Lungenklinik Krankenhaus Merheim
Studienzentrum der Lungenklinik/ Krankenhaus Merheim
Studienzentrum der Thoraxchirurgischen und Pneumologischen Klinik; Lungenkrebszentrum Köln- Merheim
Studienzentrum und Pneumologische Klinik Lungenkrebszentrum Koeln-Merheim
Studlenzentrum der Thoraxchirurgischen und Pneumologischen Klinik Lungenkrebszentrum KölnMerheim
Thoraxchirurgische u. Pneuomoonkologische Klinik
Thoraxonkologie

Clinical trials at this site (80)

Search interface

NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (M… Recruiting

2023-509165-21-00 Extrahepatic cholangiocarcinoma (eCCA) 4 2024-08-08
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting

2023-509332-26-00 Lupus Nephritis Class III-IV, +/- V 4 2023-02-16
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Ewing Sarcoma 5 2022-06-17
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting

2024-510578-25-00 Histologically proven high-risk medulloblastoma, with a 5 2021-11-05
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COM… Recruiting

2024-516330-35-00 Non-Small Cell Lung Cancer 5 2021-09-29
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Rhabdoyosarcoma 9 2020-10-07
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L… Ended

2024-515047-31-00 Patients with Limited-Stage Small Cell Lung Cancer (LS- 5 2023-08-28
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01